[go: up one dir, main page]

EA201000561A1 - Производные пиридина, пригодные в качестве активаторов глюкокиназы - Google Patents

Производные пиридина, пригодные в качестве активаторов глюкокиназы

Info

Publication number
EA201000561A1
EA201000561A1 EA201000561A EA201000561A EA201000561A1 EA 201000561 A1 EA201000561 A1 EA 201000561A1 EA 201000561 A EA201000561 A EA 201000561A EA 201000561 A EA201000561 A EA 201000561A EA 201000561 A1 EA201000561 A1 EA 201000561A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activators
glukokinase
pyridine derivatives
nephropathy
neuropathy
Prior art date
Application number
EA201000561A
Other languages
English (en)
Inventor
Ларс Торе Бургдорф
Норберт Байер
Иоганнес Глайтц
Кристин Шарон
Даньель Краво
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201000561A1 publication Critical patent/EA201000561A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Новые гетероциклические соединения формулы Iв которой R, R, R, Rи D имеют значения, указанные в п.1, являются активаторами глюкокиназы и могут применяться для предотвращения и/или лечения диабета 1 и 2 типа, ожирения, невропатии и/или нефропатии.
EA201000561A 2007-10-09 2008-08-13 Производные пиридина, пригодные в качестве активаторов глюкокиназы EA201000561A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07019691 2007-10-09
EP08001168 2008-01-23
PCT/EP2008/006649 WO2009046784A1 (en) 2007-10-09 2008-08-13 Pyridine derivatives useful as glucokinase activators

Publications (1)

Publication Number Publication Date
EA201000561A1 true EA201000561A1 (ru) 2010-10-29

Family

ID=39870670

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000561A EA201000561A1 (ru) 2007-10-09 2008-08-13 Производные пиридина, пригодные в качестве активаторов глюкокиназы

Country Status (22)

Country Link
US (1) US8420642B2 (ru)
EP (1) EP2195312B1 (ru)
JP (1) JP5567481B2 (ru)
KR (1) KR20100090250A (ru)
CN (1) CN101821264A (ru)
AR (1) AR068748A1 (ru)
AU (1) AU2008310097B2 (ru)
BR (1) BRPI0818658A2 (ru)
CA (1) CA2701806A1 (ru)
CY (1) CY1113767T1 (ru)
DK (1) DK2195312T3 (ru)
EA (1) EA201000561A1 (ru)
EC (1) ECSP10010158A (ru)
ES (1) ES2399469T3 (ru)
HR (1) HRP20120948T1 (ru)
IL (1) IL204746A0 (ru)
MX (1) MX2010003759A (ru)
NZ (1) NZ585236A (ru)
PL (1) PL2195312T3 (ru)
PT (1) PT2195312E (ru)
SI (1) SI2195312T1 (ru)
WO (1) WO2009046784A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002772A (es) 2007-09-21 2010-03-31 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201247649A (en) 2011-03-09 2012-12-01 Daiichi Sankyo Co Ltd Dipyridylamine derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
CA2866611C (en) 2012-02-28 2020-01-07 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
WO2016131192A1 (en) 2015-02-17 2016-08-25 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Compounds and methods for inducing browning of white adipose tissue
AU2016245434B2 (en) * 2015-04-07 2020-10-29 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN114685491B (zh) * 2020-12-31 2024-01-12 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178035B1 (en) * 1984-05-12 1990-01-03 FISONS plc Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
CA1305478C (en) * 1986-11-06 1992-07-21 Margaret H. Sherlock Naphthyridine and pyridopyrazine compounds and pharmaceutical usage thereof
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
AU689972B2 (en) 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
JP2004525069A (ja) 2000-06-15 2004-08-19 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのシクロアルキルアルカン酸
AU6583101A (en) * 2000-07-04 2002-01-14 Neurosearch As Aryl and heteroaryl diazabicycloalkanes, their preparation and use
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005532983A (ja) 2001-09-26 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｃ１７，２０リアーゼ阻害剤としての３‐ピリジルもしくは４‐イソキノリニルチアゾール
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
MXPA04006048A (es) * 2001-12-21 2004-09-27 Novo Nordisk As Derivados de amida como activadores de glucocinasa.
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7265138B2 (en) 2003-02-10 2007-09-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP4432901B2 (ja) * 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
WO2005021529A1 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
AU2005223610B2 (en) * 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US20050227989A1 (en) * 2004-04-13 2005-10-13 Icagen, Inc. Polycyclic thiazoles as potassium ion channel modulators
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
KR20210090744A (ko) 2004-09-02 2021-07-20 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
BRPI0608453A2 (pt) 2005-03-18 2009-12-29 Univ California compostos tendo atividade na correção de processamento de cftr mutante e usos destes
AU2006241825A1 (en) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
BRPI0608910A2 (pt) * 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
ES2397648T3 (es) * 2005-07-09 2013-03-08 Astrazeneca Ab Derivados de heteroarilbenzamida para uso como activadores de GLK en el tratamiento de la diabetes
WO2007010281A2 (en) 2005-07-21 2007-01-25 Betagenon Ab Use of thiazole derivatives and analogues in disorders caused by free fatty acids
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
CA2628274A1 (en) * 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
CA2628486A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd. Tricyclo substituted amides
JP5236499B2 (ja) * 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
AU2007235558B2 (en) 2006-03-24 2011-12-01 Array Biopharma Inc. 2 -aminopyridine analogs as glucokinase activators
US8431713B2 (en) * 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
JP2010520887A (ja) * 2007-03-09 2010-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリジン
EP2173745A2 (en) * 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
CA2701806A1 (en) 2009-04-16
AU2008310097B2 (en) 2013-05-16
US8420642B2 (en) 2013-04-16
ES2399469T3 (es) 2013-04-01
IL204746A0 (en) 2010-11-30
SI2195312T1 (sl) 2013-01-31
DK2195312T3 (da) 2013-01-02
ECSP10010158A (es) 2010-06-29
HRP20120948T1 (hr) 2012-12-31
BRPI0818658A2 (pt) 2015-04-14
CN101821264A (zh) 2010-09-01
EP2195312B1 (en) 2012-11-21
WO2009046784A1 (en) 2009-04-16
MX2010003759A (es) 2010-04-21
US20100216794A1 (en) 2010-08-26
AU2008310097A1 (en) 2009-04-16
JP5567481B2 (ja) 2014-08-06
CY1113767T1 (el) 2016-07-27
AR068748A1 (es) 2009-12-02
NZ585236A (en) 2012-03-30
PL2195312T3 (pl) 2013-04-30
EP2195312A1 (en) 2010-06-16
PT2195312E (pt) 2013-02-20
KR20100090250A (ko) 2010-08-13
JP2010540667A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
EA201000561A1 (ru) Производные пиридина, пригодные в качестве активаторов глюкокиназы
EA201001358A1 (ru) Активаторы глюкокиназы
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
EA201001367A1 (ru) Производные карбоксамид-гетероарила для лечения диабета
EA201001174A1 (ru) ПРОИЗВОДНЫЕ β-АМИНОКИСЛОТ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
EA201200653A1 (ru) Гетариламинохинолины
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
MX2008012064A (es) Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
EA201000004A1 (ru) Производные 6-(пирролопиридинил)пиримидин-2-иламина и их применение для лечения злокачественного новообразования и спида
EA201000549A1 (ru) Производные пиперидина и пиперазина
EA201001124A1 (ru) Производные хинолина и их применение в качестве фунгицидов
NZ588954A (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EA200870474A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
PE20110294A1 (es) Compuestos heterociclicos como inhibidores de enzimas de senal especifica
NO20076658L (no) Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
EA201270562A1 (ru) Арил- и гетероарилкарбонильные производные гексагидроинденопиридина и октагидробензохинолина
EA201101084A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
EA201201170A1 (ru) Гетариламинонафтиридины
EA201001407A1 (ru) Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета